Research Studies

Browse Studies

PROSPER

Enrolling
Not Enrolling
Conditions:
PSP

Criteria

Ages
50-80
Cognition
FALSE
Dyskinesias
any
Fluctuations
FALSE
Tremor
any
Gait
any
DBS
FALSE
Hallucinations
FALSE

About this study

A randomized, double-blind, placebo-controlled, Phase 2 study to assess the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) to slow the disease progression of progressive supranuclear palsy (PSP)

Sustain our mission to enhance lives and outcomes through research

As we work to improve patient quality of life — for their entire lifespan — we seek partners to catapult our progress. With your philanthropic investment, we can expand the breadth and depth of our efforts in three critical areas: research, clinical care and education and training.

Support Us